Deficient coacervation of two forms of human tropoelastin associated with supravalvular aortic stenosis.
Human tropoelastin associates by coacervation and is subsequently cross-linked to make elastin. In Williams syndrome, defective elastin deposition is associated with hemizygous deletion of the tropoelastin gene in supravalvular aortic stenosis (SVAS). Remarkably, point-mutation forms of SVAS correspond to incomplete forms of tropoelastin which include in-frame termination by nonsense mutations, yet the resulting phenotype of these disorders is not explained because expression variably occurs from both normal and mutant alleles. Proteins corresponding to two truncated tropoelastin mutants were expressed and purified to homogeneity. Coacervation of these proteins occurred as expected with increasing temperature, but substantially contrasted with that of the performance of a normal tropoelastin. Significantly, association by coacervation of the truncated SVAS tropoelastin molecules was negligible at 37 degrees C, which contrasted with the substantial coacervation seen for normal tropoelastin. Furthermore their midpoints of coacervation increased and correlated with the extent of deletion, in accord with the loss of hydrophobic regions required for tropoelastin association. Their secondary structures are similar, as evidenced by CD studies. We propose a model for point-mutation SVAS in which aberrant tropoelastin molecules are incompetent and are mainly excluded from participation in coacervation and consequently in elastogenesis. These forms of SVAS may consequently be considered functionally similar to a hemizygous deletion, and mark point-mutation SVAS as a disorder of defective coacervation.
Wu
W J
WJ
Department of Biochemistry, University of Sydney, NSW, Australia.
Weiss
A S
AS
D019943:Amino Acid Substitution; D001024:Aortic Valve Stenosis / Q000235:genetics / Q000378:metabolism*; D001808:Blood Vessels / Q000737:chemistry; D002413:Cations, Divalent / Q000494:pharmacology; D002942:Circular Dichroism; D003871:Dermatan Sulfate / Q000494:pharmacology; D004547:Elastic Tissue / Q000737:chemistry / Q000648:ultrastructure; D004548:Elasticity; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000648:ultrastructure; D016297:Mutagenesis, Site-Directed; D020125:Mutation, Missense; D011485:Protein Binding; D020033:Protein Isoforms / Q000737:chemistry* / Q000302:isolation & purification / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism; D013696:Temperature; D014333:Tropoelastin / Q000737:chemistry* / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism
D002413:Cations, Divalent; D020033:Protein Isoforms; D011993:Recombinant Fusion Proteins; D014333:Tropoelastin; D003871:Dermatan Sulfate; D006493:Heparin